FATE Logo

Fate Therapeutics, Inc. (FATE) 

NASDAQ
Market Cap
$208.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
257 of 963
Rank in Industry
153 of 552

Largest Insider Buys in Sector

FATE Stock Price History Chart

FATE Stock Performance

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Insider Activity of Fate Therapeutics, Inc.

Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $166,024 and sold $245,937 worth of Fate Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $27.68M and sold $22.12M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Redmile Group, LLC () — $2.16M.

The last purchase of 44,630 shares for transaction amount of $166,024 was made by Redmile Group, LLC () on 2023‑12‑26.

List of Insider Buy and Sell Transactions, Fate Therapeutics, Inc.

2024-08-06Saledirector
633
0.0005%
$4.23$2,678-26.11%
2024-03-04SaleChief Financial Officer
2,447
0.0027%
$7.77$19,013-46.82%
2024-01-29SaleChief Financial Officer
1,849
0.0017%
$5.00$9,245-31.21%
2024-01-09SalePresident and CEO
14,391
0.0145%
$4.37$62,889-10.43%
2024-01-09SaleChief R&D Officer
11,271
0.0114%
$4.38$49,367-10.43%
2024-01-09SaleGeneral Counsel and Secretary
10,874
0.0109%
$4.37$47,519-10.43%
2024-01-09SaleChief Financial Officer
7,028
0.0071%
$4.37$30,712-10.43%
2024-01-02SaleChief Financial Officer
5,182
0.0052%
$3.66$18,966+7.23%
2023-12-26Purchase
44,630
0.0455%
$3.72$166,024+4.69%
2023-12-18SaleChief Financial Officer
1,585
0.0018%
$3.50$5,548+23.22%
2023-11-09SaleGeneral Counsel and Secretary
24,363
0.0278%
$2.40$58,471+81.31%
2023-08-18SaleChief Financial Officer
4,718
0.0048%
$2.80$13,210+35.25%
2023-08-04Saledirector
632
0.0006%
$3.71$2,345-0.80%
2023-07-05SaleChief Financial Officer
5,182
0.0053%
$4.83$25,029-22.74%
2023-07-05SaleChief Commercial Officer
3,854
0.0039%
$4.87$18,769-22.74%
2023-06-14Saledirector
3,460
0.0036%
$5.58$19,307-28.91%
2023-04-21Purchase
256,639
0.26%
$6.18$1.59M-27.09%
2023-04-20Purchase
20,000
0.0204%
$5.99$119,800-24.29%
2023-04-18SaleChief Medical Officer
2,532
0.0027%
$6.57$16,648-26.97%
2023-04-14Sale
302,339
0.2996%
$5.84$1.77M-24.54%

Insider Historical Profitability

1.32%
Redmile Group, LLC
13180388
11.5725%
$1.8381+12.66%
Wolchko J ScottPresident and CEO
371248
0.326%
$1.83037
Valamehr BahramChief R&D Officer
158069
0.1388%
$1.83017
TAHL CINDYGeneral Counsel and Secretary
142361
0.125%
$1.83025
Dulac Edward J IIIChief Financial Officer
101479
0.0891%
$1.83013
Xu Yuandirector
8669
0.0076%
$1.8303
NELSEN ROBERT
2473188
2.1715%
$1.8310<0.0001%
ARCH VENTURE FUND VI LP10 percent owner
2473188
2.1715%
$1.8310<0.0001%
VENROCK ASSOCIATES V LP10 percent owner
2473187
2.1715%
$1.8310<0.0001%
Polaris Venture Management Co. V, L.L.C.10 percent owner
2473186
2.1715%
$1.8310<0.0001%
RASTETTER WILLIAM Hdirector
459272
0.4032%
$1.8320+1.02%
MENDLEIN JOHNdirector
282770
0.2483%
$1.8332<0.0001%
Chu Yu-WayeChief Medical Officer
140676
0.1235%
$1.8306
Plavsic MarkChief Technical Officer
123705
0.1086%
$1.8302
Shoemaker Daniel DChief Scientific Officer
73020
0.0641%
$1.83013
COUGHLIN TIMOTHY
57632
0.0506%
$1.8311+11.55%
Powl Brian T.Chief Commercial Officer
41146
0.0361%
$1.8301
Storgard ChrisChief Medical Officer
37593
0.033%
$1.8310+11.55%
Nashat Amirdirector
7539
0.0066%
$1.83120<0.0001%
Flynn Peter DSee remarks
4039
0.0035%
$1.8308
HERSHBERG ROBERT
2009
0.0018%
$1.8301
Agarwal Shefali
1840
0.0016%
$1.8302
Jooss Karin
1198
0.0011%
$1.8301
Weyer ChristianSee remarks
0
0%
$1.8302

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Redmile Group$96.66M11.5713.17M0%+$00.99
The Vanguard Group$72.75M8.719.91M+6.65%+$4.53M<0.01
BlackRock$66.79M7.999.1M-18.84%-$15.51M<0.01
Boxer Capital, LLC$60.3M7.228.22M+1,543.18%+$56.63M1.24
State Street$58.99M7.068.04M+331.63%+$45.32M<0.01
Deep Track Capital Lp$40.9M4.895.57MNew+$40.9M0.19
Bellevue Group$35.52M4.254.84M-0.24%-$86,612.000.55
Johnson & Johnson$24.8M2.973.38M0%+$00.58
Citadel Advisors LLC$22.99M2.753.13M+17.45%+$3.42M0.01
Morgan Stanley$22.5M2.693.07M+132.02%+$12.8M<0.01
D. E. Shaw & Co.$20.05M2.42.73M-23.76%-$6.25M0.02
Suvretta Capital Management, LLC$18.81M2.252.56MNew+$18.81M0.79
Assenagon Asset Management S.A.$18.7M2.242.55M+1,462.45%+$17.51M0.05
Holocene Advisors, LP$18.55M2.222.53MNew+$18.55M0.07
Deerfield Management$16.08M1.922.19MNew+$16.08M0.04
Adage Capital Partners Gp L L C$15.71M1.882.14M+25.88%+$3.23M0.03
Goldman Sachs$14.77M1.772.01M+240.49%+$10.43M<0.01
Jacobs Levy Equity Management$14.68M1.762M-23.58%-$4.53M0.05
Bank of America$14.09M1.691.92M+216.27%+$9.64M<0.01
Geode Capital Management$13.99M1.671.91M+2.28%+$311,980.04<0.01
Woodline Partners LP$13.89M1.661.89M+390.96%+$11.06M0.12
Baker Bros Advisors LP$13.35M1.61.82MNew+$13.35M0.1
JPMorgan Chase$12.91M1.551.76M-15.11%-$2.3M<0.01
Acadian Asset Management$12.58M1.511.71M-24.86%-$4.16M0.04
Point72 Asset Management$11.63M1.391.58M-54.59%-$13.98M0.02
Two Sigma Advisers LP$10.55M1.261.44M-23.4%-$3.22M0.02
OrbiMed$9.95M1.191.36M+156.66%+$6.07M0.08
Dimensional Fund Advisors$7.8M0.931.06M+231.44%+$5.45M<0.01
Federated Hermes$7.39M0.891.01M-45.54%-$6.18M0.02
Invesco$7.09M0.85965,431+645.77%+$6.14M<0.01
Charles Schwab$7.02M0.84956,331-2.71%-$195,889.93<0.01
Schonfeld Group$6.51M0.78886,925+78.29%+$2.86M0.04
Soleus Capital Management, L.P.$6.39M0.76870,000New+$6.39M0.03
Rafferty Asset Management Llc$5.36M0.64729,657New+$5.36M0.02
Northern Trust$5.26M0.63716,052+1.05%+$54,778.42<0.01
Tang Capital Management, LLC$5.14M0.62700,0000%+$00.02
Citigroup$4.57M0.55623,058-26.18%-$1.62M<0.01
Octagon Capital Advisors LP$3.82M0.46520,800New+$3.82M0.02
Gcm Grosvenor Holdings Llc$3.64M0.44495,9160%+$00.56
Hudson Bay Capital Management LP$3.38M0.4460,000New+$3.38M0.02
UBS$3.26M0.39444,050+151.87%+$1.97M<0.01
Prudential Financial$2.81M0.34383,201-31.57%-$1.3M<0.01
Voloridge Investment Management, LLC$2.78M0.33378,608New+$2.78M0.01
Artal Group S A$2.64M0.32360,311New+$2.64M0.01
Marshall Wace$2.54M0.3345,437New+$2.54M<0.01
Barclays$2.38M0.29324,243-9.78%-$257,874.99<0.01
Monaco Asset Management Sam$2.33M0.28316,805-85.49%-$13.7M1.07
BNY Mellon$2.22M0.27301,993-6.2%-$146,499.02<0.0001
Nuveen$2.2M0.26299,656-4.74%-$109,476.10<0.01
Caxton Associates$2.13M0.26290,187New+$2.13M0.09
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.